EDGAR Filing Documents for 0000950170-24-064025

Form 8-K - Current report:

SEC Accession No. 0000950170-24-064025

Filing Date

2024-05-23

Accepted

2024-05-23 17:07:21

Documents

Period of Report

2024-05-23

Items

Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Interactive Data

Document Format Files

Seq	Description	Document	Type	Size
1	8-K	cgem-20240523.htm iXBRL	8-K	71357
2	EX-99.1	cgem-ex99_1.htm	EX-99.1	56156
	Complete submission text file	0000950170-24-064025.txt		258172

Data Files

Seq	Description	Document	Type	Size
3	XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT	cgem-20240523.xsd	EX-101.SCH	25882
15	EXTRACTED XBRL INSTANCE DOCUMENT	cgem-20240523_htm.xml	XML	4889

Mailing Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142

Business Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142 617-410-4650

Cullinan Therapeutics, Inc. (Filer) CIK: 0001789972 (see all company filings)

IRS No.: 813867811 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39856 | Film No.: 24979532
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)